The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma

Hematological Oncology

Volumn 28, Issue 1, 2010, Pages 27-32

  Hyo, Rie ^a   Tomita, Naoto ^b   Takeuchi, Kengo ^c   Aoshima, Tomohiro ^a   Fujita, Atsuko ^a   Kuwabara, Hideyuki ^a   Hashimoto, Chizuko ^d   Takemura, Sachiya ^e   Taguchi, Jun ^f   Sakai, Rika ^a   Fujita, Hiroyuki ^b   Fujisawa, Shin ^a   Ogawa, Koji ^g   Motomura, Shigeki ^d   Suzuki, Ritsuro ^h   Ishigatsubo, Yoshiaki ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e Fujisawa City Hospital   (Japan)

^f SHIZUOKA RED CROSS HOSPITAL   (Japan)

^g Yokosuka City Hospital   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; CANCER STAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD5; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950884566     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.896     Document Type: Article

References (50)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392. (Pubitemid 24273002)
2. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In Tumours of Haematopoietic and Lymphoid Tissues: Pathology and Genetics. World Health Organization Classification of Tumours. Jaffe ES, Harris NL, Stein H, Vardiman JW. (eds). IARC Press: Lyon, France, 2001; 171-174.
3. Kume M, Suzuki R, Yatabe Y, et al. Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997; 88: 1087-1093.
4. Taniguchi M, Oka K, Hiasa A, et al. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998; 91: 1145-1151.
5. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999; 13: 1441-1447.
6. Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999; 105: 1133-1139.
7. Kroft SH, Howard MS, Picker LJ, Ansari MQ, Aquino DB, McKenna RW. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000; 114: 523-533.
8. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
9. Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003; 101: 699-702.
10. Karnan S, Tagawa H, Suzuki R, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Gene Chromosomes Cancer 2004; 39: 77-81.
11. Tagawa H, Tsuzuki S, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 2004; 64: 5948-5955.
12. Kobayashi T, Yamaguchi M, Kim S, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5(+) and CD5(-) diffuse large B-Cell lymphomas. Cancer Res 2003; 63: 60-66.
13. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
14. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633. (Pubitemid 38970553)
15. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
16. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
17. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
18. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
19. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
20. Tomita N, Motomura S, Hyo R, et al. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Cancer 2007; 109: 1146-1151.
21. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
22. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003; 17: 1948-1960.
23. Gascoyne RD. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol 2004; 16: 436-441.
24. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive NHL. N Engl J Med 1993; 329: 987-994.
25. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
26. Salles G, Shipp MA. Workshop on biological prognostic factors in aggressive non-Hodgkin's lymphomas. Ann Oncol 1999; 10(suppl. 3): 12.
27. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
28. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
29. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
30. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
31. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
32. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
33. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968.
34. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
35. Winter JN,Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-4213.
36. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 1102-1109.
37. Nyman H, Adde M, Karjalainen-Lindsberg M-L, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
38. Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003; 9: 722-728.
39. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large Bcell lymphoma. Blood 2005; 106: 1770-1777.
40. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008; 93: 1195-1202.
41. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-1926.
42. Kanda M, Suzumiya J, Ohshima K, Tamura K, Kikuchi M. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. Leuk Lymphoma 1999; 34: 569-580.
43. Estalilla OC, Koo CH, Brynes RK, Medeiros LJ. Intravascular large B-cell lymphoma; a report of five cases initially diagnosed by bone marrow biopsy. Am J Clin Pathol 1999; 112: 248-255.
44. Yegappan S, Coupland R, Arber DA, et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Mod Pathol 2001; 14: 1147-1156.
45. Ito M, Kim Y, Choi JW, Ozawa H, Fujino M. Prevalence of intravascular large B-cell lymphoma with bone marrow involvement at initial presentation. Int J Hematol 2003; 77: 159-163.
46. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007; 109: 478-485.
47. Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26: 3189-3195.
48. Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patient with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol 2007; 136: 276-285.
49. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and postgerminal center biomarkers. J Clin Oncol 2008; 26: 2717-2724.
50. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.